Evgen is a clinical stage drug development company focused on the treatment of cancer and neurological conditions. Evgen’s pipeline is based on our proprietary Sulforadex® technology, and includes a number of synthetic, stabilised analogues of the naturally occurring compound sulforaphane. Many peer-reviewed scientific papers have identified the medical potential of sulforaphane in multiple indications. Our objective is to use our Sulforadex® technology to turn this scientific promise into commercially successful products, addressing important clinical needs.
Evgen is a privately held company owned by its management team, venture capital investors and private individuals. Its largest shareholders are the North West Fund for Biomedical and EV Group.Find out more
Our clinical pipeline is based on our proprietary Sulforadex® platform technology. Phase I studies have been successfully completed and we are progressing three clinical programmes into Phase II. The three programmes - targeting prostate cancer, breast cancer and subarachnoid haemorrhage – benefit from a substantial body of academic scientific data.
Stabilisation technology in Sulforadex® means that sulforaphane can be delivered as a stable active in an oral pharmaceutical product.Find out more